CHEK vs. ABIO, LNSR, RMTI, ANEB, DRRX, EQ, INAB, BGXX, CTCX, and CASI
Should you be buying Check-Cap stock or one of its competitors? The main competitors of Check-Cap include ARCA biopharma (ABIO), LENSAR (LNSR), Rockwell Medical (RMTI), Anebulo Pharmaceuticals (ANEB), DURECT (DRRX), Equillium (EQ), IN8bio (INAB), Bright Green (BGXX), Carmell (CTCX), and CASI Pharmaceuticals (CASI). These companies are all part of the "medical" sector.
Check-Cap (NASDAQ:CHEK) and ARCA biopharma (NASDAQ:ABIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Check-Cap received 247 more outperform votes than ARCA biopharma when rated by MarketBeat users. Likewise, 65.49% of users gave Check-Cap an outperform vote while only 41.98% of users gave ARCA biopharma an outperform vote.
1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 56.4% of ARCA biopharma shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 30.9% of ARCA biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ARCA biopharma's return on equity of -16.08% beat Check-Cap's return on equity.
ARCA biopharma is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.
In the previous week, Check-Cap had 5 more articles in the media than ARCA biopharma. MarketBeat recorded 6 mentions for Check-Cap and 1 mentions for ARCA biopharma. Check-Cap's average media sentiment score of 0.79 beat ARCA biopharma's score of 0.47 indicating that Check-Cap is being referred to more favorably in the media.
Check-Cap has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
Summary
ARCA biopharma beats Check-Cap on 7 of the 12 factors compared between the two stocks.
Get Check-Cap News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHEK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHEK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Check-Cap Competitors List
Related Companies and Tools
